Full Report

Format

Full Report
Summary (Text)
Summary (XML)

Send to:

Choose Destination

File
Clipboard
Collections

Malignant Lymphoma, Large Cell Type

MedGen UID:: 309381
•Concept ID:: C1518189
•: Neoplastic Process

Definition

An antiquated term that refers to a morphologic variant of non-Hodgkin lymphoma which is composed predominantly or exclusively of large neoplastic lymphocytes. [from NCI]

Term Hierarchy

GTR
MeSH

CClinical test, RResearch test, OOMIM, GGeneReviews, VClinVar

CROGVMalignant Lymphoma, Large Cell Type

Neoplasm
- Neoplasm by Special Category
  - Neoplasm by Obsolete Classification
    - Hematopoietic and Lymphoid Neoplasm (Antiquated)
      - Lymphoma by Working Formulation (Antiquated)
        Malignant Lymphoma by Cell Type (Working Formulation)
        Malignant Lymphoma, Large Cell Type
        Adult Diffuse Large Cell Lymphoma
        Recurrent Adult Diffuse Large Cell Lymphoma
        Stage I Adult Diffuse Large Cell Lymphoma
        Stage II Adult Diffuse Large Cell Lymphoma
        Stage II Contiguous Adult Diffuse Large Cell Lymphoma
        Stage II Non-Contiguous Adult Diffuse Large Cell Lymphoma
        Stage III Adult Diffuse Large Cell Lymphoma
        Stage IV Adult Diffuse Large Cell Lymphoma
        AIDS-Related Diffuse Large Cell Lymphoma
        Childhood Large Cell Lymphoma
        Childhood Diffuse Large Cell Lymphoma
        Recurrent Childhood Large Cell Lymphoma
        Stage I Childhood Large Cell Lymphoma
        Stage II Childhood Large Cell Lymphoma
        Stage III Childhood Large Cell Lymphoma
        Stage IV Childhood Large Cell Lymphoma
        Malignant Lymphoma, Histiocytic, Diffuse
        Malignant Lymphoma, Large Cell, Cleaved and Non-Cleaved

Professional guidelines

PubMed

Primary central nervous system lymphoma.

Ferreri AJM, Calimeri T, Cwynarski K, Dietrich J, Grommes C, Hoang-Xuan K, Hu LS, Illerhaus G, Nayak L, Ponzoni M, Batchelor TT
Nat Rev Dis Primers 2023 Jun 15;9(1):29. doi: 10.1038/s41572-023-00439-0. PMID: 37322012 Free PMC Article

Treatment strategies for patients with diffuse large B-cell lymphoma.

Poletto S, Novo M, Paruzzo L, Frascione PMM, Vitolo U
Cancer Treat Rev 2022 Nov;110:102443. Epub 2022 Jul 31 doi: 10.1016/j.ctrv.2022.102443. PMID: 35933930

Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA).

Hayden PJ, Roddie C, Bader P, Basak GW, Bonig H, Bonini C, Chabannon C, Ciceri F, Corbacioglu S, Ellard R, Sanchez-Guijo F, Jäger U, Hildebrandt M, Hudecek M, Kersten MJ, Köhl U, Kuball J, Mielke S, Mohty M, Murray J, Nagler A, Rees J, Rioufol C, Saccardi R, Snowden JA, Styczynski J, Subklewe M, Thieblemont C, Topp M, Ispizua ÁU, Chen D, Vrhovac R, Gribben JG, Kröger N, Einsele H, Yakoub-Agha I
Ann Oncol 2022 Mar;33(3):259-275. Epub 2021 Dec 16 doi: 10.1016/j.annonc.2021.12.003. PMID: 34923107

See all (738)

Recent clinical studies

Etiology

Updates in the Classification of T-cell Lymphomas and Lymphoproliferative Disorders.

Oishi N, Ahmed R, Feldman AL
Curr Hematol Malig Rep 2023 Dec;18(6):252-263. Epub 2023 Oct 23 doi: 10.1007/s11899-023-00712-9. PMID: 37870698 Free PMC Article

Extranodal T- and NK-cell lymphomas.

de Leval L, Feldman AL, Pileri S, Nakamura S, Gaulard P
Virchows Arch 2023 Jan;482(1):245-264. Epub 2022 Nov 7 doi: 10.1007/s00428-022-03434-0. PMID: 36336765 Free PMC Article

Classification and diagnostic evaluation of nodal T- and NK-cell lymphomas.

Feldman AL, Laurent C, Narbaitz M, Nakamura S, Chan WC, de Leval L, Gaulard P
Virchows Arch 2023 Jan;482(1):265-279. Epub 2022 Oct 10 doi: 10.1007/s00428-022-03412-6. PMID: 36210383

Epstein-Barr virus-associated T- and NK-cell lymphoproliferative diseases: an update and diagnostic approach.

Hue SS, Oon ML, Wang S, Tan SY, Ng SB
Pathology 2020 Jan;52(1):111-127. Epub 2019 Nov 22 doi: 10.1016/j.pathol.2019.09.011. PMID: 31767131

International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes.

Vose J, Armitage J, Weisenburger D; International T-Cell Lymphoma Project
J Clin Oncol 2008 Sep 1;26(25):4124-30. Epub 2008 Jul 14 doi: 10.1200/JCO.2008.16.4558. PMID: 18626005

See all (5127)

Diagnosis

Intratumor heterogeneity and T cell exhaustion in primary CNS lymphoma.

Heming M, Haessner S, Wolbert J, Lu IN, Li X, Brokinkel B, Müther M, Holling M, Stummer W, Thomas C, Schulte-Mecklenbeck A, de Faria F, Stoeckius M, Hailfinger S, Lenz G, Kerl K, Wiendl H, Meyer Zu Hörste G, Grauer OM
Genome Med 2022 Sep 24;14(1):109. doi: 10.1186/s13073-022-01110-1. PMID: 36153593 Free PMC Article

Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment.

van der Horst HJ, de Jonge AV, Hiemstra IH, Gelderloos AT, Berry DRAI, Hijmering NJ, van Essen HF, de Jong D, Chamuleau MED, Zweegman S, Breij ECW, Roemer MGM, Mutis T
Blood Cancer J 2021 Feb 18;11(2):38. doi: 10.1038/s41408-021-00430-6. PMID: 33602901 Free PMC Article

The role of inflammation in lymphoma.

Carbone A, Tripodo C, Carlo-Stella C, Santoro A, Gloghini A
Adv Exp Med Biol 2014;816:315-33. doi: 10.1007/978-3-0348-0837-8_12. PMID: 24818728

Diagnosis and treatment of diffuse large B-cell lymphoma.

Mey U, Hitz F, Lohri A, Pederiva S, Taverna C, Tzankov A, Meier O, Yeow K, Renner C
Swiss Med Wkly 2012;142:w13511. Epub 2012 Jan 30 doi: 10.4414/smw.2012.13511. PMID: 22290632

Reactive immunoblastic proliferations.

Nathwani BN, Brynes RK
Semin Diagn Pathol 1988 Nov;5(4):317-28. PMID: 3064216

See all (7913)

Therapy

Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial.

Thieblemont C, Phillips T, Ghesquieres H, Cheah CY, Clausen MR, Cunningham D, Do YR, Feldman T, Gasiorowski R, Jurczak W, Kim TM, Lewis DJ, van der Poel M, Poon ML, Cota Stirner M, Kilavuz N, Chiu C, Chen M, Sacchi M, Elliott B, Ahmadi T, Hutchings M, Lugtenburg PJ
J Clin Oncol 2023 Apr 20;41(12):2238-2247. Epub 2022 Dec 22 doi: 10.1200/JCO.22.01725. PMID: 36548927 Free PMC Article

Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC.

Olsen EA, Whittaker S, Willemze R, Pinter-Brown L, Foss F, Geskin L, Schwartz L, Horwitz S, Guitart J, Zic J, Kim YH, Wood GS, Duvic M, Ai W, Girardi M, Gru A, Guenova E, Hodak E, Hoppe R, Kempf W, Kim E, Lechowicz MJ, Ortiz-Romero P, Papadavid E, Quaglino P, Pittelkow M, Prince HM, Sanches JA, Sugaya M, Vermeer M, Zain J, Knobler R, Stadler R, Bagot M, Scarisbrick J
Blood 2022 Aug 4;140(5):419-437. doi: 10.1182/blood.2021012057. PMID: 34758074 Free PMC Article

Follicular lymphoma: 2020 update on diagnosis and management.

Freedman A, Jacobsen E
Am J Hematol 2020 Mar;95(3):316-327. Epub 2019 Dec 22 doi: 10.1002/ajh.25696. PMID: 31814159

Anti-CD19 CAR T-Cell Therapy for B-Cell Non-Hodgkin Lymphoma.

Abramson JS
Transfus Med Rev 2020 Jan;34(1):29-33. Epub 2019 Aug 29 doi: 10.1016/j.tmrv.2019.08.003. PMID: 31677848

Blinatumomab: a historical perspective.

Nagorsen D, Kufer P, Baeuerle PA, Bargou R
Pharmacol Ther 2012 Dec;136(3):334-42. Epub 2012 Aug 24 doi: 10.1016/j.pharmthera.2012.07.013. PMID: 22940266

See all (4562)

Prognosis

Comparison of 2-year outcomes with CAR T cells (ZUMA-1) vs salvage chemotherapy in refractory large B-cell lymphoma.

Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Reagan PM, Miklos DB, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T, Lin Y, Crump M, Kuruvilla J, Van Den Neste E, Farooq U, Navale L, DePuy V, Kim JJ, Gisselbrecht C
Blood Adv 2021 Oct 26;5(20):4149-4155. doi: 10.1182/bloodadvances.2020003848. PMID: 34478487 Free PMC Article

CAR T cell therapy for B-cell lymphomas.

Chavez JC, Locke FL
Best Pract Res Clin Haematol 2018 Jun;31(2):135-146. Epub 2018 Apr 11 doi: 10.1016/j.beha.2018.04.001. PMID: 29909914 Free PMC Article

Diffuse large B-cell lymphoma.

Li S, Young KH, Medeiros LJ
Pathology 2018 Jan;50(1):74-87. Epub 2017 Nov 20 doi: 10.1016/j.pathol.2017.09.006. PMID: 29167021

Epstein-Barr Virus-associated Lymphoproliferative Disorders in the Skin.

Goodlad JR
Surg Pathol Clin 2017 Jun;10(2):429-453. Epub 2017 Mar 18 doi: 10.1016/j.path.2017.01.001. PMID: 28477890

T-cell-rich B-cell lymphoma.

Rodriguez J, Pugh WC, Cabanillas F
Blood 1993 Sep 1;82(5):1586-9. PMID: 8364208

See all (6200)

Clinical prediction guides

Characterization of immune exhaustion and suppression in the tumor microenvironment of splenic marginal zone lymphoma.

Anagnostou T, Yang ZZ, Jalali S, Kim HJ, Larson DP, Tang X, Yu Y, Pritchett JC, Bisneto JV, Price-Troska TL, Mondello P, Novak AJ, Ansell SM
Leukemia 2023 Jul;37(7):1485-1498. Epub 2023 Apr 28 doi: 10.1038/s41375-023-01911-2. PMID: 37117318

Clinical prognosis and bioinformatic analysis of primary thyroid lymphoma.

Bai Z, Li L, Guan T, Wang J, Zhao J, Su L
Medicine (Baltimore) 2021 Feb 12;100(6):e24598. doi: 10.1097/MD.0000000000024598. PMID: 33578562 Free PMC Article

Navigating the cutaneous B-cell lymphomas: avoiding the rocky shoals.

Jaffe ES
Mod Pathol 2020 Jan;33(Suppl 1):96-106. Epub 2019 Oct 25 doi: 10.1038/s41379-019-0385-7. PMID: 31653979

The Function of MicroRNAs in B-Cell Development, Lymphoma, and Their Potential in Clinical Practice.

Zheng B, Xi Z, Liu R, Yin W, Sui Z, Ren B, Miller H, Gong Q, Liu C
Front Immunol 2018;9:936. Epub 2018 Apr 30 doi: 10.3389/fimmu.2018.00936. PMID: 29760712 Free PMC Article

Diffuse aggressive B-cell lymphomas.

Said J
Adv Anat Pathol 2009 Jul;16(4):216-35. doi: 10.1097/PAP.0b013e3181a9d5d2. PMID: 19546610

See all (4788)

Recent systematic reviews

Late relapse after CAR-T cell therapy for adult patients with hematologic malignancies: A definite evidence from systematic review and meta-analysis on individual data.

Zinzi A, Gaio M, Liguori V, Cagnotta C, Paolino D, Paolisso G, Castaldo G, Nicoletti GF, Rossi F, Capuano A, Rafaniello C
Pharmacol Res 2023 Apr;190:106742. Epub 2023 Mar 22 doi: 10.1016/j.phrs.2023.106742. PMID: 36963592

Toxicity and efficacy of CAR T-cell therapy in primary and secondary CNS lymphoma: a meta-analysis of 128 patients.

Cook MR, Dorris CS, Makambi KH, Luo Y, Munshi PN, Donato M, Rowley S, Saad A, Goy A, Dunleavy K, Ali A
Blood Adv 2023 Jan 10;7(1):32-39. doi: 10.1182/bloodadvances.2022008525. PMID: 36260735 Free PMC Article

Targeted therapy for advanced anaplastic lymphoma kinase (<I>ALK</I>)-rearranged non-small cell lung cancer.

Cameron LB, Hitchen N, Chandran E, Morris T, Manser R, Solomon BJ, Jordan V
Cochrane Database Syst Rev 2022 Jan 7;1(1):CD013453. doi: 10.1002/14651858.CD013453.pub2. PMID: 34994987 Free PMC Article

Relapse Prevention with Tyrosine Kinase Inhibitors after Allogeneic Transplantation for Philadelphia Chromosome-Positive Acute Lymphoblast Leukemia: A Systematic Review.

Warraich Z, Tenneti P, Thai T, Hubben A, Amin H, McBride A, Warraich S, Hannan A, Warraich F, Majhail N, Kalaycio M, Anwer F
Biol Blood Marrow Transplant 2020 Mar;26(3):e55-e64. Epub 2019 Sep 23 doi: 10.1016/j.bbmt.2019.09.022. PMID: 31557532

Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis.

Grigor EJM, Fergusson D, Kekre N, Montroy J, Atkins H, Seftel MD, Daugaard M, Presseau J, Thavorn K, Hutton B, Holt RA, Lalu MM
Transfus Med Rev 2019 Apr;33(2):98-110. Epub 2019 Feb 14 doi: 10.1016/j.tmrv.2019.01.005. PMID: 30948292

See all (70)

MedGen

National Center for Biotechnology Information